Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals (VNDA)
:VNDA
Holding VNDA?
Track your performance easily
Earnings Data
Report Date
Feb 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.04Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: -9.20%
|Next Earnings Date:Aug 01, 2018
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance for Fanapt and successful integration of PONVORY, with promising pipeline developments. However, challenges such as the decline in HETLIOZ revenue, FDA denial for tradipitant, and PONVORY sales decrease were notable setbacks.Company Guidance
During the Q3 2024 earnings call for Vanda Pharmaceuticals, key metrics highlighted included a 23% increase in total revenues to $47.7 million compared to Q3 2023, driven by the introduction of PONVORY revenue and increased Fanapt sales. Fanapt's new patient starts, as captured by the IQVIA NBRx metric, grew by over 90% compared to Q3 2023. The sales force for Fanapt expanded to 150 representatives, with plans to reach 200 by year-end. PONVORY's net product sales were $5.9 million, reflecting a decrease attributed to temporary inventory destocking. The company provided an updated 2024 revenue guidance, projecting total net product sales between $190 million and $210 million, citing growth momentum across its product portfolio. Additionally, Vanda's cash position as of September 30, 2024, was $376.3 million.Fanapt Sales Force Expansion
Completion of the first phase of Fanapt sales force build-out with 150 representatives, leading to a 90% increase in new patient starts compared to Q3 2023.
PONVORY Transition Success
Successful transition of PONVORY from Janssen, with positive clinician and patient reception, and plans for indication expansions in psoriasis and ulcerative colitis.
Fanapt Revenue Growth
Fanapt net product sales increased by 12% year-over-year to $23.9 million in Q3 2024.
Overall Revenue Increase
Total revenues for Q3 2024 increased by 23% compared to Q3 2023, driven by Fanapt and PONVORY.
Pipeline Expansion and Progress
Initiation of Phase III program for milsaperidone in major depressive disorder and upcoming NDA for tradipitant in motion sickness.
---
VNDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VNDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $4.89 | $5.02 | +2.66% |
| Jul 31, 2024 | $5.84 | $5.64 | -3.42% |
| May 08, 2024 | $5.36 | $5.01 | -6.53% |
| Feb 07, 2024 | $3.64 | $4.07 | +11.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vanda Pharmaceuticals (VNDA) report earnings?
Vanda Pharmaceuticals (VNDA) is schdueled to report earning on Feb 05, 2025, TBA Not Confirmed.
What is Vanda Pharmaceuticals (VNDA) earnings time?
Vanda Pharmaceuticals (VNDA) earnings time is at Feb 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNDA EPS forecast?
VNDA EPS forecast for the fiscal quarter 2024 (Q4) is -0.11.
---